Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma

European Journal of Cancer

Volumn 47, Issue 9, 2011, Pages 1287-1298

  Porta, Camillo ^a   Osanto, Susanne ^b   Ravaud, Alain ^c   Climent, Miguel Angel ^d   Vaishampayan, Ulka ^e   White, Dorothy A ^f   Creel, Patricia ^g   Dickow, Brenda ^e   Fischer, Patricia ^f   Gornell, Suzanne Sweeney ^f   Meloni, Federica ^a   Motzer, Robert J ^f  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c HÔPITAL SAINT ANDRÉ   (France)

^d INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^e KARMANOS CANCER INSTITUTE   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g DUKE UNIVERSITY   (United States)

Author keywords

Adverse events; Everolimus; Patient management; Renal cell carcinoma; Safety

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; ATORVASTATIN; CORTICOSTEROID; ENTECAVIR; EVEROLIMUS; FATTY ACID; FIBRIC ACID DERIVATIVE; FLUCONAZOLE; LAMIVUDINE; MAMMALIAN TARGET OF RAPAMYCIN; METHYLPREDNISOLONE; MOUTHWASH; NICOTINIC ACID; NYSTATIN; PLACEBO; PRAVASTATIN; PREDNISONE; SIMVASTATIN; SORAFENIB; SUNITINIB; TENOFOVIR; VASCULOTROPIN;

ACUTE RESPIRATORY FAILURE; ADVANCED CANCER; ADVERSE OUTCOME; ANEMIA; ASTHENIA; BACTERIAL INFECTION; CANCER SURVIVAL; CREATININE BLOOD LEVEL; DIARRHEA; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INTERSTITIAL LUNG DISEASE; KIDNEY CARCINOMA; KIDNEY METASTASIS; LIFESTYLE MODIFICATION; LYMPHOCYTOPENIA; METABOLIC DISORDER; MUCOSA INFLAMMATION; MULTICENTER STUDY (TOPIC); MYCOSIS; NAUSEA; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT INDICATION; VIRUS INFECTION;

AGED; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PLACEBOS; PNEUMONIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RISK; SIROLIMUS; STOMATITIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79957566962     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.02.014     Document Type: Article

References (31)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. J. Ferlay, P. Autier, and M. Boniol Estimates of the cancer incidence and mortality in Europe in 2006 Ann Oncol 18 2007 581 592 (Pubitemid 46359643)
3. A.M. Molina, and R.J. Motzer Current algorithms and prognostic factors in the treatment of metastatic renal cell carcinoma Clin Genitourin Cancer 6 2008 s7 s13
4. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Kidney Cancer. V.2.2010.
5. C. Coppin, L. Le, F. Porzsolt, and T. Wilt Targeted therapy for advanced renal cell carcinoma Cochrane Database Syst Rev 2 2008 CD006017
6. S. Oudard, J. Medioni, and J. Ayllon Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma Expert Rev Anticancer Ther 9 2009 705 717
7. J. Brugarolas Renal-cell carcinoma - molecular pathways and therapies N Engl J Med 356 2007 185 187 (Pubitemid 46089681)
8. G.V. Thomas, C. Tran, and I.K. Mellinghoff Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer Nat Med 12 2006 122 127 (Pubitemid 43050086)
9. R.J. Motzer, B. Escudier, and S. Oudard Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449 456
10. R.J. Motzer, B. Escudier, and S. Oudard Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors Cancer 116 2010 4256 4265
11. R.J. Motzer, J. Bacik, and L.H. Schwartz Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma J Clin Oncol 22 2004 454 463 (Pubitemid 41079774)
12. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
13. D. Cho, S. Signoretti, M. Regan, J.W. Mier, and M.B. Atkins The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer Clin Cancer Res 13 2 Suppl 2007 758s 763s
14. I. Duran, L.L. Siu, and A.M. Oza Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus Eur J Cancer 42 2006 1875 1880 (Pubitemid 44149096)
15. D.A. White, P. Camus, and M. Endo Non-infectious pneumonitis after everolimus therapy for advanced renal cell carcinoma Am J Respir Crit Care Med 182 2010 396 403
16. Afinitor prescribing information. Basel, Switzerland: Novartis Pharma AG; 2010.
17. C.G. Alexopoulos, M. Vaslamatzis, and G. Hatzidimitriou Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours Br J Cancer 81 1999 69 74 (Pubitemid 29415493)
18. W. Yeo, P.K. Chan, and S. Zhong Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors J Med Virol 62 2000 299 307
19. A. Marzano, E. Angelucci, and P. Andreone Prophylaxis and treatment of hepatitis B in immunocompromised patients Dig Liver Dis 39 2007 397 408 (Pubitemid 46508732)
20. European Association for the Study of the Liver EASL clinical practice guidelines: management of chronic hepatitis B J Hepatol 50 2009 227 242
21. W.J. Köstler, M. Hejna, W. Wenzel, and C.C. Zielinski Oral mucositis complicating chemotherapy and/or radiotherapy: options for prevention and treatment CA Cancer J Clin 51 2001 290 315 (Pubitemid 34232774)
22. M.A. Stokman, F.K. Spijkervet, and H.M. Boezen Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: results of meta-analyses J Dent Res 85 2006 690 700 (Pubitemid 44297322)
23. C.M. Potting, R. Uitterhoeve, W.S. Op Reimer, and T. Van Achterberg The effectiveness of commonly used mouthwashes for the prevention of chemotherapy-induced oral mucositis: a systematic review Eur J Cancer Care (Engl) 15 2006 431 439 (Pubitemid 44893370)
24. D.J. Harris, J. Eilers, A. Harriman, B.J. Cashavelly, and C. Maxwell Putting evidence into practice®: evidence-based interventions for management of oral mucositis Clin J Oncol Nurs Pract 12 2007 141 152
25. D.M. Nathan, J.B. Buse, and M.B. Davidson Medical management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy Diabetes Care 32 2009 193 203
26. National Institutes of Health. National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final report. .
27. J. Genest, J. Forhlich, G. Fodor, and R. McPherson Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: 2003 update CMAJ 169 2003 1 10
28. International task force for prevention of coronary heart disease. Treatment guidelines for dyslipidemia. .
29. G.I. Kirchner, I. Meier-Wiedenbach, and M.P. Manns Clinical pharmacokinetics of everolimus Clin Pharmacokinet 43 2004 83 95 (Pubitemid 38283132)
30. J.M. Kovarik, S. Hartmann, and J. Figueiredo Effect of rifampin on apparent clearance of everolimus Ann Pharmacother 36 2002 981 985 (Pubitemid 34564379)
31. T.E. Hutson, R.A. Figlin, J.G. Kuhn, and R.J. Motzer Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies Oncologist 13 2008 1084 1096